



## **Sosei Subsidiary Heptares Therapeutics wins UK Best Established Biotech Company Award at OBN Annual Awards 2016**

**Tokyo, Japan –7 October 2016:** Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565) today announces Heptares Therapeutics (“Heptares”), the wholly-owned subsidiary of Sosei, has been announced as the winner of the Best Established Biotech Company Award at the OBN Annual Awards ceremony celebrating outstanding achievement in the UK life sciences sector, held last night in Oxford, UK.

The award was presented to Malcolm Weir, Founder and CEO of Heptares, and Executive Vice President and Chief R&D Officer of Sosei.

Heptares received the award in recognition of its outstanding success during the 18 months since its acquisition by Sosei Group in February 2015. This success is highlighted by four partnerships signed with major pharmaceutical companies around its pipeline and technology (Allergan, AstraZeneca, Pfizer and Teva), as well as significant R&D progress. These deals have been transformational for Heptares (and Sosei), providing expertise and resource for its partnered pipeline, validation for its approach and industry leading platform and substantial financial resources to drive its growth strategy forwards, including the advancement of its in-house R&D pipeline.

This award was judged by a panel of leading figures from the UK life sciences industry.

Read the OBN press release [here](#).

OBN is the membership organisation supporting and bringing together the UK’s emerging life sciences companies, corporate partners and investors. [www.obn.org.uk](http://www.obn.org.uk)

-Ends-

### **Notes to Editors**

#### **About the OBN Annual Awards – [www.obn-awards.com](http://www.obn-awards.com)**

The OBN Awards, now in their 8th year, celebrate innovation and achievement across the UK life sciences industry. The awards remain independent with categories that cover Biotech, Medtech, Synthetic Biology and Digital Health and recognise achievements from emerging to late stage R&D companies to large pharma and life sciences investors.

#### **About Heptares Therapeutics**

Heptares is a clinical-stage company creating transformative medicines targeting G protein-coupled receptors (GPCRs), a superfamily of 375 receptors linked to a wide range of human diseases. Heptares’ proprietary StaR® technology and structure-based drug design (SBDD) capabilities enable us to engineer and develop drugs for highly validated, yet historically undruggable or challenging GPCRs. Using this approach, we are building an exciting pipeline of new medicines (small molecules and biologics) with the potential to transform the treatment of Alzheimer’s disease, schizophrenia, cancer immune-oncology, migraine, addiction, metabolic disease and other indications. We

have partnerships for our novel candidates and technologies with leading pharmaceutical and biotechnology companies, including Allergan, AstraZeneca, Kymab, MedImmune, MorphoSys, Pfizer and Teva.

Heptares is a wholly owned subsidiary of Sosei Group Corporation. For more information, please visit [www.heptares.com](http://www.heptares.com) and [www.osei.com](http://www.osei.com).

### **About Sosei**

Sosei is a biopharmaceutical company originating from Japan but with global presence. Sosei's primary business model is based on identifying novel and/or differentiated product assets or technology platforms and, through supporting these in preclinical and clinical development and establishing commercial partnerships, advancing new medicines to patients worldwide. For further information about Sosei, please visit [www.osei.com/en](http://www.osei.com/en).

Contact for Sosei  
Harumi BANSE, Investor Relations  
+81-(0)3-5210-3399  
hbanse@osei.com

### **Forward-looking statements**

*This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Sosei's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.*